Latest CD133 Stories
LOS ANGELES, May 19, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd.
LOS ANGELES, April 30, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd.
Stem cells taken from ALS patients may have the same capacity to develop into mature neuron-like cells as those collected from healthy donors, according to a new study released this month in STEM
A nutritional supplement could stimulate the production of stem cells integral for repairing the body.
Researchers at the PontifÃcia Universidade CatÃ³lica do ParanÃ¡ and Instituto Carlos Chagas have evaluated the therapeutic potential of purified and expanded CD133+ cells human umbilical cord blood (HUCB)-derived in treating myocardial infarction by intramyocardially injecting them into a rat model.
TAIPEI, Taiwan, Dec.
BERGISCH GLADBACH, Germany, October 29 /PRNewswire/ -- Miltenyi Biotec announces the treatment of the first patient in a phase III clinical trial termed PERFECT.
ImmunoCellular Therapeutics, a biotechnology company, has filed a provisional US patent application relating to its vaccine technology targeting cancer stem cells. The vaccine technology is exclusively licensed from Cedars-Sinai Medical Center.
ImmunoCellular Therapeutics has exclusively licensed from Cedars-Sinai Medical Center, certain novel peptides which can stimulate the immune system to target cancer stem cells in gliomas, a cancer originating in the brain or spine.
- A young chicken: also used as a pet name for children.